Zacks.com on MSN1d
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost ...
Moderna was a huge pandemic name, but has struggled since the earlier days of the health crisis. The company is looking to introduce new products and then lower its R&D budget. Even after its sell ...
On Thursday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Moderna Inc (NASDAQ:MRNA). This decision comes amidst a backdrop of mixed analyst sentiments and Moderna’s ...
Hosted on MSN1mon
Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027Moderna said it plans to cut $1.1 billion in expenses by 2027 as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product ...
Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback